Endothelial dysfunction is a critical event in vascular inflammation characterized, in part, by elevated surface expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is heavily N-glycosylated, and like other surface proteins, it is largely presumed that fully processed, complex N-glycoforms are dominant. However, our recent studies suggest that hypoglycosylated or high mannose (HM)-ICAM-1 N-glycoforms are also expressed on the cell surface during endothelial dysfunction, and have higher affinity for monocyte adhesion and regulate outside-in endothelial signaling by different mechanisms. Whether different ICAM-1 N-glycoforms are expressed in vivo during disease is unknown. In this study, using the proximity ligation assay, we assessed the relative formation of high mannose, hybrid and complex α-2,6-sialyated N-glycoforms of ICAM-1 in human and mouse models of atherosclerosis, as well as in arteriovenous fistulas (AVF) of patients on hemodialysis. Our data demonstrates that ICAM-1 harboring HM or hybrid epitopes as well as ICAM-1 bearing α-2,6-sialylated epitopes are present in human and mouse atherosclerotic lesions. Further, HM-ICAM-1 positively associated with increased macrophage burden in lesions as assessed by CD68 staining, whereas α-2,6-sialylated ICAM-1 did not. Finally, both HM and α-2,6-sialylated ICAM-1 N-glycoforms were present in hemodialysis patients who had AVF maturation failure compared to successful AVF maturation. Collectively, these data provide evidence that HM-ICAM-1 N-glycoforms are present in vivo, and at levels similar to complex α-2,6-sialylated ICAM-1 underscoring the need to better understand their roles in modulating vascular inflammation.
Introduction
Inflammation is a carefully orchestrated response involving the release of pro-inflammatory factors and homing of immune cells to injured tissue. The vascular endothelium is a key player in the inflammatory process, responding to stressors such as oscillatory blood flow (that occurs a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Materials and methods

Materials
DuoLink1 proximity ligation assay kit was purchased from ThermoFisher (Waltham, MA). HistoPrep™ was purchased from Fisher Scientific (Hampton, NH). Anti-human ICAM-1 antibody was purchased from ThermoFisher (BMS108), and anti-mouse ICAM-1 antibody was purchased from Abcam (25375) (Cambridge, UK). Concanavalin A (ConA), Sambucus Nigra (SNA), Hippeastrum Hybrid Amaryllis (HHL), and Maackia Amurensis Lectin II (MAL-II) lectins were purchased from Vector laboratories (Birlingame, CA). Anti-ICAM-1 and avidin were conjugated to oligomer probes using the DuoLink Probemaker kits (Sigma) per manufacturer provided protocols. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
Human vessel collection and processing
Human specimens were collected at the University of Alabama at Birmingham or Louisiana State University Health Sciences Center according to procedures and protocols approved by the University of Alabama at Birmingham Institutional Review Board and Louisiana State University Health Sciences Center Institutional Review Board respectively. Human arteries were obtained post-mortem, after authorization of autopsy that includes permission to remove tissues for research purposes. Vessel segments were fixed using formalin (10%) for 24h and then embedded in paraffin. Lesion type was determined according to the Stary scale from 1-5
Proximity-ligation assay (PLA) schematic and lectin specificity. Biotinylated lectins with indicated specificities were added to first label specific sugars. Then, anti-ICAM-1 antibody and avidin, conjugated to complementary oligos, were added. When lectin-recognized sugar epitopes are less than 40 nm from anti-ICAM-1, the complementary oligos hybridize and amplify, producing red fluorescent puncta. Right panel shows Nglycan structures recognized by different lectins used (adapted from [19] . Man = Mannose; Gal = Galactose; GlcNac = N-acetylglucosamine; Sa = Sialic acid; R = varying N-glycan structures.
https://doi.org/10.1371/journal.pone.0230358.g001
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ICAM-1 N-glycoforms in endothelial dysfunction [20] by a cardiovascular pathologist using the defining characteristics of fibrosis, calcification, and fatty deposits. All procedures were performed per Institutional Review Board approved protocols.
In addition, human vein samples were collected from subjects at the time of 1 st and 2 nd stage basilic vein transposition surgery. At the time of both surgeries, a circumferential piece of vein (~10-15 mm and adjacent to site of anastomosis creation) was excised and immediately stored in formalin for histology and immunohistochemistry (IHC) studies. Each venous tissue sample was embedded in paraffin as previously described [21] . Following paraffin embedding, each piece was sliced into 5μM sections for histological studies. These vein samples were collected under approval by the University of Alabama at Birmingham Institutional Review Board. Donor specimens from cadaveric donors at the time of organ harvesting were obtained using services from the National Disease Research Interchange, Philadelphia, PA, and fixed in formalin, as previously described [22] . [8] [9] [10] week old male ApoE-/-mice were fed a high fat, Western-type diet (21% fat by weight, 0.15% cholesterol, and 19.5% casein without sodium cholate) for 12 weeks, and the innominate artery (i.e. brachiocephalic) and left carotid arteries collected for histological analysis. Both lesion and non-lesion areas of the same segment were analyzed and lesions identified by the presence of increased neointimal hyperplasia compared to non-lesion segments. Carotid arteries were also collected from male ApoE-/-mice fed a control diet. In the second model, [8] [9] [10] week old, male ApoE-/-mice underwent partial ligation of the left carotid artery to induce disturbed flow as described previously [19, 20] . After induction of anesthesia (5% isoflurane, followed by 2% isoflurane for maintenance of anesthesia), the external, internal, and occipital arteries were ligated with a 7-0 silk suture leaving the superior thyroid artery patent, and the resulting disturbed flow pattern was verified by ultrasound measurements using a VisualSonics VEVO3100 system. When this model is performed in atherosclerosis-prone ApoE-/-mice, accelerated atherosclerosis develops in the left carotid artery due to disturbed flow compared to the paired right carotid artery [21] . Mice were euthanized by pneumothorax under isoflurane anesthesia, and then ex-sanguinated followed by vessel collection. For all samples, the adventitia was carefully removed and vessel segments fixed in formalin (10%) for 24h and then embedded in paraffin blocks for mounting to slides. All procedures were performed according to LSU Health Sciences Center-Shreveport and University of Alabama at Birmingham IACUC approved protocols.
Mouse vessel collection and processing
Tissue immunofluorescence
Paraffin-embedded serial tissue sections were rehydrated using standard protocols. Briefly, slides were treated with xylene followed by decreasing Histoprep concentrations (100%, 95%, 85%, 75%) before immersion in 1x PBS. Antigen retrieval was accomplished using 10mM sodium citrate buffer (pH 6.0) and heated for 12 minutes in the microwave. Following antigen retrieval, tissues were washed in PBS and proximity-ligation, total ICAM-1, or CD68 staining performed as outlined below.
Proximity-ligation assay
Briefly, 20 μg of the following biotinylated lectins: HM and hybrid N-glycan-specific lectin ConA, the α2,6-sialyation specific lectin SNA, the HM-specific lectin HHL, or the α2,3-sialylation specific lectin MAL-II were added for 30 minutes at 4˚C (see Table 1 ). These lectins were chosen to provide broad coverage of different N-glcyan structures. After washing twice with PBS, samples were blocked with 1X Carbo-Free blocking solution (Vector Labs) for 30 min at 20-25˚C. Immediately following blocking, samples were incubated with oligo-tagged avidin or anti-ICAM-1 (10 μg/mL) for one hour at 37˚C followed by ligation and amplification steps as per the protocol. Both anti-mouse and human ICAM-1 antibodies recognize extracellular (domain 1) epitopes on ICAM-1. Slides were left to dry and mounted using the DuoLink1 mounting medium containing DAPI.
Total ICAM-1 and CD68 immunofluorescence
Slides were processed as described above. After blocking, slides were incubated with mouse or human anti-ICAM-1 or CD68 O/N at 4˚C, followed by a 1 hour incubation at 20-25˚C with the species-appropriate secondary antibody conjugated to Alexa Fluor 594. After washing, slides were left to dry and mounted using DuoLink1 mounting medium containing DAPI.
Image acquisition and analysis
Images were acquired on a BioTek Lionheart live cell imager using DAPI (377/447), GFP (469/ 525), and Texas Red (586/647) filters. LED intensity, camera gain, and integration time for each channel was uniform across all samples. Images at three random locations within lesion and non-lesion areas were recorded per section. Images were collected at 4x and 60x magnification. Image quantification was performed using either Gen5 (Biotek) or ImageJ software (NIH). To quantify PLA images, 3 random fields per group, per experiment were selected and number of puncta counted using ImageJ particle analysis software (NIH).
Statistics
All statistical analysis was performed using GraphPad Prism software. Paired student t-tests were utilized in comparing the different areas (lesion vs. non-lesion) from the same vessel or left and right carotids from the same animal. Unpaired t-test was used to compare human vessels with different lesion stages. A p-value less than 0.05 was considered significant. 
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Results
Hypoglycosylated ICAM-1 is present in mouse atherosclerotic lesions
Vessels from ApoE-/-mice were collected after 12 weeks feeding of a control or high fat diet, with the latter being an established method to reproducibly promote atherosclerosis [7, 22, 23] . Total ICAM-1 levels (measured using an anti-ICAM-1 antibody that binds to epitopes on the N-glycan-devoid domain 1 of the protein) were detected on the luminal surface of lesions, consistent with prior reports of up-regulation of this adhesion molecule on the endothelium [24] [25] [26] (Fig 2A) . No ICAM-1 was detected on areas of the vessel devoid of lesions, nor on vessels collected from mice fed a normal chow diet. To determine which N-glycoforms of ICAM-1 were present, we used the PLA assay (Fig 1) , where red puncta indicate positive staining that the two epitopes are within 40nm of each other. To measure HM and hybrid ICAM-1, samples were labeled with biotinylated ConA, followed by treatment with avidin and an anti-ICAM-1 antibody both tagged with complementary oligonucleotides. High mannose N-glycans, α-2,6-sialylation, and α-2,3-sialylation on ICAM-1 were measured using the same method with HHL, SNA and MAL-II lectins, respectively. Fig 2A shows red puncta for the ICAM-1 N-glycoforms in lesion areas only; no PLA staining was observed in non-lesion areas of the same vessels nor in vessels from ApoE-/-mice fed normal chow (control diet). As an immunostaining control, the antibody against ICAM-1 or avidin were excluded (Fig 2B and 2C respectively) and showed no PLA-positive staining associated with lesions. Fig 2D and 2E shows that total ICAM-1 and HM / hybrid N-glycoforms of ICAM-1 were significantly increased in lesion vs. non-lesion regions, with similar trends with α-2,6-sialylated ICAM-1 noted (p<0.07). Macrophage burden was assessed by CD68 staining in lesion and non-lesion regions; these measurements were performed on serial sections from the same preparations used for proximity ligation assay staining. CD68 staining was significantly higher in lesion areas compared to non-lesion areas (Fig 2F and 2G) . Note: Since different lectins will bind their target epitopes with distinct affinities, direct comparison between lectins is not possible. We also collected vessels from ApoE-/-mice that underwent partial carotid ligation, which creates oscillatory flow in the left carotid artery while leaving the right carotid artery as an internal control. This model rapidly causes endothelial dysfunction and atherosclerosis [19] . Both the left and right carotid arteries from mice that underwent partial ligation were collected 7 days post-ligation and stained for total ICAM-1 and ICAM-1 N-glycoforms. Fig 3A-3C show representative images and quantification of ICAM-1 and ICAM-1 N-glycoform staining. Total ICAM-1, HM / hybrid N-glycoforms were increased in the ligated left carotid artery (LC) compared to the control right carotid artery (RC). CD68 staining was also significantly higher in the LC compared to the control RC (Fig 3D and 3E) . Fig 4A-4C show correlations between CD68 staining and HM / hybrid, HM, and α-2,6-sialylated, ICAM-1 respectively, from ApoE-/-mice fed high fat diets and Fig 4D-4F after partial carotid ligation. Significant positive correlations were observed between CD68 and HM / hybrid and HM-ICAM-1 in both mouse models, but only HFD-fed mice had a significant positive correlation between CD68 and α-2,6-sialylated, ICAM-1.
HM / hybrid and α2,6-sialylated ICAM-1 are present in advanced human atherosclerotic lesions
To determine whether distinct ICAM-1 N-glycoforms are present in human atherosclerosis and whether they were dependent on disease severity, human vessels were collected at autopsy and luminal surface total ICAM-1 and HM / hybrid, α2,3-sialylated, and α2,6-sialylated ICAM-1 were measured via PLA. Table 1 summarizes patient demographics, vessel location, 
PLOS ONE
ICAM-1 N-glycoforms in endothelial dysfunction and lesion type. ICAM-1 expression increased as a function of disease severity with staining visible in type 3 and 5 lesions (Fig 5A and 5B) . Similarly, HM-/ hybrid, α-2,6-sialylation, and α-2,3-sialylation N-glycoforms were only detected in advanced lesions (Fig 5A and 5C) -Fig 5D   Fig 3. HM / hybrid, HM, and α-2 
ICAM-1 N-glycoforms in endothelial dysfunction and 5E show specificity for HM / hybrid and sialylated-ICAM-1 staining; no PLA-positive staining was observed when individual PLA reagents were omitted.
Finally, CD68 staining was significantly higher in advanced lesions compared to earlier stage lesions (Fig 6A and 6B) or compared to IgG control staining of advanced lesions. Further, CD68 staining had a significant positive correlation with HM-ICAM-1 levels with a trend towards significance (P<0.09) noted for correlation between α-2,6-sialyated ICAM-1 and CD68 levels. (Fig 6C-6E) . 
HM / hybrid and α2,6-sialylated ICAM-1 are present in patients on hemodialysis with failed AVFs
Advanced chronic kidney disease (CKD) patients that reach end-stage renal disease require hemodialysis. A common limitation with this therapy is failure of the AVF to successfully mature due to endothelial dysfunction and inflammation mediated in part by oscillatory flow [27, 28] . Basilic vein samples from CKD patients that had undergone surgical AVF creation were obtained and subjected to PLA for HM/hybrid, α-2,3-sialylated, and α-2,6-sialylated 
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ICAM-1 N-glycoforms in endothelial dysfunction ICAM-1. Table 2 shows patient demographics, and the success vs. failure status of AVF. Fig  7A show representative images indicating that total ICAM-1, HM / hybrid, α-2,6-sialylated, and α-2,3-sialylated ICAM-1 were present in the failed AVFs. Little to no ICAM-1 was detected in successful AVFs (Fig 7A and 7B) . HM / hybrid and α-2,6-sialylated ICAM-1 levels were significantly higher in failed AVFs compared to successful AVFs, with α-2,3-sialylated ICAM-1 also being elevated (p<0.06) (Fig 7C) . No staining for ICAM-1 or associated N-glycoforms (only tested with ConA and SNA) were observed in control (no AVF) healthy donor veins (n = 3).
Discussion
Inflammation is a carefully orchestrated process involving the homing of immune cells to inflamed tissues, a process mediated by adhesion molecules on the endothelial cell surface [5] . Surface adhesion molecules are heavily N-glycosylated with~20-50% of their observed molecular weights attributed to N-glycans. While insights into the role of protein N-glycosylation in regulating inflammation have primarily focused on circulating immune cells (e.g. CD44 and other selectin ligands on neutrophils and T-cells [10, 21, 29] , relatively little attention has been paid to the impact N-glycans may have on the function of endothelial adhesion molecules in diseases mediated by endothelial dysfunction.
ICAM-1 is a well-established mediator of increased monocyte-endothelial interactions and interestingly, compared to the related adhesion molecule, VCAM-1, contains more N-glycans as a proportion of its overall molecular weight (~50% in ICAM-1 vs.~25% in VCAM-1) [30] . Numerous studies have shown that deletion of ICAM-1 or blocking its ability to engage Mac-1 or LFA-1 on leukocytes prevents inflammation [31] [32] [33] [34] . It is also known that N-glycosylation can modulate ICAM-1 function. For example, Mac-1 binding is higher to ICAM-1 bearing HM structures [35] . Moreover, different ICAM-1 N-glycoforms may regulate tumor burden and inflammatory signaling, and that the degree of ICAM-1 N-glycosylation can change depending on the cell in which it is expressed [36] [37] [38] [39] [40] . In our previous work, we showed that HM / hybrid ICAM-1 was formed in activated endothelial cells, and this hypoglycosylated ICAM-1 N-glycoform mediated higher affinity binding to monocytes compared to fully processed, sialylated ICAM-1 N-glycoforms. In addition, ligation dependent interactions between ICAM-1 and the actin cytoskeleton was also distinctly regulated between HM / hybrid ICAM-1 and complex-ICAM-1 [15, 30] .
While the aforementioned studies suggest altered functions for hypoglycosylated vs. complex sialylated ICAM-1, whether these N-glycoforms are expressed in disease is not known and important to establish translational significance. By using vessels from patients with varying stages of atherosclerotic lesions, from CKD patients with successful or failed AVFs, and from two atherosclerotic mouse models (ApoE-/-mice fed high-fat diet and ApoE-/-mice post-partial carotid ligation), we show that HM / hybrid and complex ICAM-1 N-glycoforms are found in vascular lesions but not in non-lesion areas. Interestingly, HM / hybrid ICAM-1 levels displayed stronger correlations with CD68 macrophage staining in human and mouse lesions, suggesting that hypoglycosylated ICAM-1 may play a more prominent role in mediating monocyte recruitment compared to α-2,6-sialyated ICAM-1. Consistent with this hypothesis, our previous data showed that the affinity of monocyte adhesion to HM / hybrid ICAM-1 was greater compared to α-2,6-sialyated ICAM-1 [18, 30] .
To date, very few studies have focused on N-glycosylation of endothelial cells and their role in disease. The complexity of studying surface adhesion proteins and their N-glycan patterns may be a contributing factor to the lack of studies in this area. For example, ICAM-1 contains 8 putative N-glycosylation sites. This, coupled with the different possible combination of N-linked sugars ranging from HM-to complex N-glycans, means that ICAM-1 may exist in >200,000 possible N-glycoforms (calculated from data in Lau et al [41] . This complexity clearly makes identification of specific N-glycoforms challenging [17, 42] . It is for this reason we employed 4 different lectins in this study to identify different ICAM-1 N-glycoforms. By using lectins that recognize high-mannose, hybrid, and two different types of sialic acid linkages, we detected ICAM-1 decorated with at least 4 different types of N-glycans in vivo (Note: ConA and HHL have some overlapping N-glycan binding specificities). To our knowledge, this data represents the first study demonstrating distinct N-glycoforms on ICAM-1 in vivo. We do note limitations of our study, namely the sole reliance on the PLA assay to discern HM, hybrid, and sialylated-ICAM-1 and that this assay only informs on spatial proximity; it is possible that HM-epitopes on other proteins and ICAM-1 are co-expressed. However, our previous data show that ICAM-1 immunoprecipitated from human atherosclerotic lesions has a similar molecular weight (75KDa) to HM / hybrid ICAM-1; complex ICAM-1 is close to 100KDa, supports conclusions that a HM-ICAM-1 N-glycoform is present in vivo [15] . An additional limitation is quantitation of PLA-positive puncta. Differential affinities for binding between specific N-glycan structures and the different lectins could lead to different staining intensities. For this reason, we quantified data based only on the number of positive puncta and not on staining intensity. However, we recognize that relative differences in lectin binding may have affected sensitivity for detecting discreet PLA-positive puncta. Potential limitations in detection also preclude definitive conclusions regarding temporal expression of ICAM-1 and its N-glycoforms as a function of disease. Type 2 lesions are characterized by lipid laden macrophages; however neither ICAM-1 protein, nor its N-glycoforms, were detectable in these lesions in our methods. ICAM-1 expression in early atherosclerosis has been studied, and in some cases has been found to be minimal in earlier stages of the disease [43, 44] , which may explain the lack of detection in our methods. Further, the role of ICAM-1 in early atherosclerosis is still debated [45] , and our data suggests this HM-ICAM-1 may be important in later stages of the disease.
Further studies using more specific and selective approaches for N-glycan analyses are required to determine the exact N-glycoforms of ICAM-1 present in vascular inflammation and their function. Little is known about the regulation and control of different N-glycoforms, and if the regulation may be disease specific. For example, while our data showed little α-2,3-sialylated ICAM-1 in human atherosclerosis, it was present in failed AVFs from humans. This observation perhaps indicates that regulation of N-glycoforms depends on the disease state. Future studies in the lab will focus on the regulation of N-glycans during inflammation; specifically by looking at the enzymes responsible for N-glycosylation, such as α-mannosidases and glycosyltransferases. Distinct biological functions of ICAM-1 N-glycoforms may also have therapeutic implications. Attempts to therapeutically target ICAM-1 to abrogate atherosclerosis in vivo have been successful in animal models; for example, ICAM-1 deficiency and anti-ICAM-1 antibody treatment protects against atherosclerosis in ApoE-deficient mice [34, 46] . However, anti-ICAM-1 therapies have not translated into humans. Treatment with functional blocking anti-ICAM-1 antibodies have had no effect in improving kidney allograft rejection rates nor mortality rates in stroke patients, and in fact induced a neutrophil-dependent pro-inflammatory response in stroke patients [47] [48] [49] . Moreover, a general concern with a long-term anti ICAM-1 therapeutic strategy is the potential for inhibiting innate immunity [50] . ICAM-1 is a diverse protein with functions spanning mitogenic signaling, leukocyte adhesion, and cell survival mechanisms [51] [52] [53] , and therefore global targeting can result in a potentially detrimental disruption of normal responses. Our findings that different N-glycoforms of ICAM-1 are expressed, coupled with these having distinct functions [15, 18] , may offer new therapeutic strategies that involve targeting hypoglycosylated HM-ICAM1 specifically. We posit that blocking HM / hybrid ICAM-1 may lead to selective attenuation of monocyte ingress into atheroprone endothelial beds. A better understanding of the glycosylation patterns of the activated endothelium throughout the course of disease may yield more selective therapeutics that target endothelial inflammation in a disease and vascular bed-specific manner.
